Please assess the completion status of the following clinical trial:

Trial Title: Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults ages 20 and older~2. Confirmed clinical (meeting at least 3 of the 4 Curaçao Criteria) or genetic diagnosis of HHT~3. Epistaxis Severity Score (ESS) ≥ 4 and 2 or more nosebleeds per week with a cumulative nosebleed duration of at least 5 minutes per week~4. Stable nasal hygiene and medical regimen for preceding 1 month~5. Stable epistaxis pattern over the preceding 3 months~Exclusion Criteria:~1. Contraindications for systemic β adrenergic blocker administration~   1. Hypersensitivity to β adrenergic blockers~  2. Asthma or bronchospasm~  3. Congestive heart failure with LVEF \<40%~  4. Hereditary pulmonary arterial hypertension~  5. Baseline bradycardia (HR \<55 beats per minute)~  6. Sick Sinus Syndrome~  7. 2nd or 3rd degree heart block, left or right bundle branch block, or bifasicular block~  8. Uncontrolled diabetes mellitus (most recent HbA1c \>9%) or diabetic ketoacidosis within last 6 months~  9. Hypotension (systolic blood pressure \< 90)~2. Known hypersensitivity to timolol~3. Severe peripheral circulatory disturbances (Raynaud phenomenon)~4. Known intermediate or poor metabolizer variant of the liver enzyme CYP2D6~5. Current use of any of the following known strong CYP2D6 inhibitors: fluoxetine (Prozac), paroxetine (Paxil), bupropion (Welbutrin), quinidine, quinine, ritonavir (Norvir), and terbinafine (Lamisil)~6. Current use of the following other drugs known to pharmacodynamically interact with timolol: diltiazem, verapamil, digoxin, digitalis, propafenone, disopyramide, clonidine, flecainide, or lidocaine~7. Patients currently treated or who plan to initiate treatment with β-blockers~8. Use of any anti-angiogenic medication in the last month prior to recruitment, including bevacizumab, pazopanib, thalidomide, or lenalidomide~9. Illicit drug use, except marijuana~10. Known pheochromocytoma~11. Use of anticoagulants, antiplatelet, or fibrinolytic therapies within the last month prior to recruitment, except for low-dose (81 mg or less) of aspirin~12. Pregnancy or planned pregnancy in the next 6 months or currently breastfeeding~13. Inability to read or understand English~14. Inability to complete 8 weeks of therapy for any reason

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Timolol Gel Arm (Type: EXPERIMENTAL): Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
- Placebo Gel Arm (Type: PLACEBO_COMPARATOR): Participants in the placebo gel arm will receive the gel itself with no active medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete